Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Opendoor Shares Plunge Following Major Investor Exit and Scathing Critique

Dieter Jaworski by Dieter Jaworski
September 24, 2025
in Analysis, Nasdaq, Real Estate & REITs, Trading & Momentum
0
Opendoor Stock
0
SHARES
144
VIEWS
Share on FacebookShare on Twitter

Opendoor Technologies Inc. saw its stock price plummet by 15.51% on Tuesday, closing at $7.08. The sharp decline was triggered by a dual blow: a substantial share sale by a major investor and a public denouncement of the company’s business model by a prominent hedge fund manager. This sell-off effectively erased the recent optimism that had surrounded a significant management overhaul.

Hedge Fund Manager Launches Public Attack

Adding significant pressure to the stock, hedge fund manager George Noble took to the social media platform X to deliver a harsh assessment of the iBuying firm. He labeled the company “total garbage,” pointing to its persistent financial losses, what he termed “catastrophic unit economics,” and a “miserable balance sheet.” These public remarks resonated with existing investor concerns regarding the high costs and inherent risks of Opendoor’s operational approach.

The market’s reaction was swift and severe:
– The stock experienced high volatility, trading within a range of $8.10 to $6.91.
– The closing price settled near the day’s lowest point.
– Trading volume surged well above average levels.

Major Stakeholder Access Industries Drastically Cuts Position

Selling pressure intensified with the disclosure that Access Industries, a principal shareholder, had divested approximately 11.4 million shares. This transaction, valued at $95.2 million, slashes the investment firm’s stake to around 4.2% of Opendoor’s outstanding shares. This marks the second significant disposal by Access Industries within the month, signaling a notable erosion of confidence from a key investor.

Should investors sell immediately? Or is it worth buying Opendoor?

New Leadership Faces Immediate Test

The current downturn presents a stark contrast to the situation just weeks prior. On September 11, the share price had skyrocketed by as much as 80% following news of a top-level management reshuffle. The appointment of Kaz Nejatian as the new Chief Executive Officer and the return of company co-founders to the board of directors had been met with enthusiastic approval from the market.

However, the recent massive share sale raises serious questions about the credibility of this nascent turnaround narrative. Underlying challenges, including reports of slow-moving real estate inventory and pressure from fluctuating mortgage rates, continue to squeeze profit margins.

Attention is now firmly fixed on Opendoor’s incoming executive team, which is scheduled to assume formal control in October. The market will be watching closely for a strategic plan that addresses the pointed criticisms about the company’s journey toward sustainable profitability. The stock’s performance in the near term will serve as a critical gauge of whether this sell-off is perceived as a temporary setback or a more profound reevaluation of the company’s worth.

The next significant event for investors will be the release of the company’s third-quarter 2025 financial results, expected in early November. This report will provide the new leadership with their first major platform to outline their strategic vision. It will also allow the market to evaluate the company’s performance against the weak Q3 guidance previously issued in August. Having fallen substantially from its 52-week high of $10.52, reached recently, the stock is now navigating a period of elevated risk and uncertainty.

Ad

Opendoor Stock: Buy or Sell?! New Opendoor Analysis from February 8 delivers the answer:

The latest Opendoor figures speak for themselves: Urgent action needed for Opendoor investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Opendoor: Buy or sell? Read more here...

Tags: Opendoor
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

KemPharm Stock
Analysis

Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion

February 8, 2026
SuRo Capital Stock
AI & Quantum Computing

SuRo Capital Sharpens Focus on AI Infrastructure Investments

February 8, 2026
Chicago Atlantic Real Estate Finance Stock
Analysis

Tax Clarity and Sector Optimism Bolster Outlook for Chicago Atlantic

February 8, 2026
Next Post
Tesla Stock

Tesla Shares Poised for Rally as UBS Raises Delivery Forecast

Vici Properties Stock

Vici Properties: Market Hesitation Meets Strategic Expansion

Evolent Health Stock

Evolent Health Sells Primary Care Division in Strategic Shift

Recommended

FCBC stock news

Impax Asset Management Group plc Reduces Stake in Snap Inc. as Insiders Sell Off Shares

2 years ago
The Trade Desk Stock

The Trade Desk: A Market Conundrum of Conflicting Signals

3 months ago
Intel Stock

US Government Holds Massive Intel Share Position, Creating Market Uncertainty

5 months ago
Nuvalent Stock

Nuvalent Shares Surge on Promising Clinical Trial Results

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Tax Clarity and Sector Optimism Bolster Outlook for Chicago Atlantic

RBB Bancorp Reports Strong Asset Quality Improvement and Strategic Capital Review

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

DroneShield Shares Face Headwinds Despite Record Performance

Rock Tech Lithium: Investors Await the Final Go-Ahead

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Trending

KemPharm Stock
Analysis

Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion

by Kennethcix
February 8, 2026
0

Zevra Therapeutics continues to build its profile as a dedicated rare disease company. Recent clinical data presentations...

Oak Valley Stock

Oak Valley Bancorp Surpasses $2 Billion Milestone with Record Annual Profit

February 8, 2026
SuRo Capital Stock

SuRo Capital Sharpens Focus on AI Infrastructure Investments

February 8, 2026
Chicago Atlantic Real Estate Finance Stock

Tax Clarity and Sector Optimism Bolster Outlook for Chicago Atlantic

February 8, 2026
RBB Stock

RBB Bancorp Reports Strong Asset Quality Improvement and Strategic Capital Review

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion
  • Oak Valley Bancorp Surpasses $2 Billion Milestone with Record Annual Profit
  • SuRo Capital Sharpens Focus on AI Infrastructure Investments

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com